Chardan Capital Initiates Coverage On Cognition Therapeutics with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has initiated coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rating and set a price target of $11.
June 06, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has initiated coverage on Cognition Therapeutics with a Buy rating and set a price target of $11.
The initiation of coverage with a Buy rating and a price target of $11 by Chardan Capital is likely to positively impact the stock price of Cognition Therapeutics in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100